Clinical Trial Update: Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating acalabrutinib and venetoclax with or without early obinutuzumab for high-risk, recurrent, or refractory chronic lymphocytic le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Calquence (acalabrutinib) (acalabrutinib)
• Gazyva (obinutuzumab) (obinutuzumab)
• Venclyxto (venetoclax) (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING